Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3526
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research Institute of Infectious Diseases
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular (for Inactivated Formulation)
01
Overview
V3526 is a live-attenuated vaccine candidate developed for the prevention of Venezuelan equine encephalitis (VEE), a mosquito-borne viral disease that affects both humans and animals. The vaccine is derived by site-directed mutagenesis from a virulent clone of the Venezuelan equine encephalitis virus (VEEV) IA/B Trinidad donkey strain. It has been evaluated in preclinical studies and clinical trials for its safety, immunogenicity, and protective efficacy. Both live-attenuated and formalin-inactivated versions have been studied. The mechanism of action involves induction of neutralizing antibodies against multiple subtypes of VEE virus, providing protection against systemic infection and central nervous system involvement[1][2][6][8]. The vaccine has shown robust immunogenicity in animal models and early human studies.
- Brand names
- V3526V-3526V 3526
- Other names
- Venezuelan equine encephalitis virus vaccine candidate V3526fV3526 (formalin-inactivated version)VRP 3526 (virus replicon particle platform)
Beyond the preview
Go deeper on V3526.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3526.